[ad_1]
The board of administrators of CuraTeQ Biologics Pvt Ltd, at its assembly held on Thursday, accredited the growth of its operations by establishing one other mammalian cell tradition manufacturing facility of upper capability to cater to the long run necessities, Aurobindo Pharma mentioned in a regulatory submitting.
“The capital expenditure for ramping up capacities is estimated to be round Rs 300 crore,” it mentioned, including that the ability is more likely to be totally operational by FY26.
Additional, the board additionally accredited coming into into contract manufacturing operations (CMO) for biologicals for efficient utilisation of capacities.
This might increase the enterprise prospects on this space as the worldwide biologics contract manufacturing demand is rising at 8-10 per cent and CuraTeQ will actively search prospects in CMO space, it added.
The corporate additional mentioned the board of its one other wholly-owned subsidiary, Auro Vaccines Pvt Ltd, has additionally accredited exploring potentialities to supply contract manufacturing service to world vaccine builders to successfully utilise its current manufacturing capability.
Auro Vaccines is engaged within the enterprise of creating and manufacturing vaccines biologicals.
[ad_2]
Source link
